1. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial 
Prof Richard E Clark, MD, Fotios Polydoros, MSc, Prof Jane F Apperley, MD, Dragana Milojkovic, PhD, Christopher Pocock, PhD, Graeme Smith, MD, Jenny L Byrne, PhD, Hugues de Lavallade, MD, Prof Stephen G O'Brien, PhD, Tony Coffey, Prof Letizia Foroni, PhD, Prof Mhairi Copland, PhD 
The Lancet Haematology 
Volume 4, Issue 7, Pages e310-e316 (July 2017)
DOI: /S (17)
Copyright © 2017 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
MMR=major molecular response (BCR-ABL1:ABL1 ratio consistently <0·1%). MR4=deep molecular response (BCR-ABL1:ABL1 ratio <0·01%). TKI=tyrosine kinase inhibitor.
The Lancet Haematology 2017 4, e310-e316DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions

3. Figure 2 Relapse-free survival (A) and time to MMR recovery (B)
MMR=major molecular response (BCR-ABL1:ABL1 ratio consistently <0·1%). MR4=deep molecular response (BCR-ABL1:ABL1 ratio <0·01%). HR=hazard ratio.
The Lancet Haematology 2017 4, e310-e316DOI: ( /S (17) )
Copyright © 2017 Elsevier Ltd Terms and Conditions